Only after completing such functional validations can the efficacy of GZMB and SPP1 as therapeutic targets in IBC be firmly established, and conclusive evidence be provided for our proposed model of immunosuppressive microenvironment remodeling. Here, GZMB is linked to inflammatory breast carcinoma.